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Objective Assessment of Intracardiac Conduction to Guide Permanent
Pacemaker Implantation Following Alcohol Septal Ablation for Hypertrophic
Obstructive Cardiomyopathy
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Background: After alcohol septal ablation (ASA) for hypertrophic obstructive car-
diomyopathy (HOCM); the onset, duration and recurrence of CHB necessitating a
permanent pacemaker (PPM) placement are unpredictable and typically require in-
hospital monitoring for up to 6-8 days. We present a protocol for early risk stratiﬁ-
cation and identifying those who will need a PPM
Methods: ASA is performed at our center since 1999. A subset of patients, were
consented for an electrophysiologic study (EPS) on day 4 post procedure with the goal
of measuring intracardiac HV interval and identifying those patients that required
permanent pacemaker implantation.
Results: From 1999 to 2014; 86 ASA procedures were performed in 83 patients, and
49 of them had an EPS. Except for 3 patients with a deﬁbrillator (ICD) prior to the
ASA, EPSs were done on those who do not carry a PPM or ICD. HV interval was
measured on those with either no change in AV conduction, or with new bundle
branch/ fascicular block or transient intraprocedural CHB, however, 4 patients were
found to have CHB at the time of procedure. HV duration was < 70 milliseconds (ms)
In 35/49 (71%) and  70 ms in 14/49 (9%). Of the 14 patients with HV  70, 12
underwent PPM implantation before discharge and two did not (one already had an
ICD, and the other one had HV at 70 ms with a known prior Left BBB and was judged
to be safe for discharge with monitoring). At the time of EPS surface ECG in those 12
patients showed CHB in 2 patients, while in the other 10 there were no signs of high
degree AV block and PPM was indicated based on the ﬁnding of the EPS only. At
follow up of a median of 8 months; 5 of those 10 were found to be pacemaker
dependent. In those who did not undergo a PPM implantation: 3 lost follow up but the
rest were alive and free from PPM indications.
Conclusions: In patients without persistent complete AV block following ASA, a
strategy of measuring intracardiac HV interval on day four post procedure with a 70
ms threshold for PPM implantation, is helpful to identify a very high-risk subgroup of
patients whose surface ECG would not have otherwise indicated a PPM.
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Background: Medical treatment for hypertrophic obstructive cardiomyopathy
(HOCM) is limited and is for symptoms only. Surgical myomectomy has been used
with low mortality. Alcohol Septal Ablation (ASA) has also been used for symptom
relief, but sometimes pacemaker placement is required. Coil embolization of the septal
perforator branch artery has been proposed as an alternative for ASA with similar
results and reduced complications.
Methods: We performed a retrospective, nonrandomized investigation evaluating the
safety and efﬁcacyof septal branchcoil embolization in symptomatic patientswithHOCM.
Results: Twenty patients (9 males, 11 females) with HOCM and drug-refractory
symptoms underwent coil embolization of the septal artery. 16 patients were func-
tional class III (80%) and 4 patients were class IV (20%) at baseline. Patients were
followed for 33 months on average. NYHA functional class signiﬁcantly improved
(p< 0.00001) with the majority of patients in functional class I (12, 60%) or II
(7, 35%) and only 1 patient remained in NYHA class III (5%). LVOT gradient
signiﬁcantly decreased on the follow-up echocardiogram (77.6  39.8 vs. 20.6  19.2
mmHg; p< 0.00001, respectively). Interventricular septal thickness was also reduced
over time (16.8  2.7 vs. 18.7  2.3 mm, p¼0.0069, respectively). Three patients
underwent a second procedure with subsequent clinical improvement in 2 of them.
A fourth patient underwent surgical myomectomy. None of the study patients required
PPM implantation. 3 patients received ICD due to ventricular arrhythmias.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Alcohol SConclusions: The results of this pilot non-randomized study suggest that the use of
coil for septal ablation was safe and effective in patients with symptomatic HOCM.
Compared with previous reports based on ASA, coil embolization possibly improves
the safety of the procedure.Cardiogenic Shock and Hemodynamic Support Devices
Washington Convention Center, Lower Level, Hall A
Saturday, September 13, 2014, 5:00 PM–7:00 PM
Abstract nos: 65-74
TCT-65
The Efﬁcacy and Safety of Mechanical Hemodynamic Support in Patients
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Cardiogenic Shock: Bayesian Approach Network Meta-Analysis of 13
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Background: Studies have reported conﬂicting results regarding efﬁcacy of me-
chanical hemodynamic support using intra-aortic balloon pump (IABP) or percuta-
neous left ventricular assisted device (LVAD) in patients undergoing high-risk PCI.
We performed a frequentist and Bayesian meta-analysis comparing the safety and
efﬁcacy of IABP, LVAD, and medical therapy (MT).
Methods: RCTs comparing overall mortality of IABP versus MT or IABP versus
LVAD in high-risk PCI populations, regardless of accompanying cardiogenic shock
were included to this network meta-analysis. The pre-speciﬁed primary endpoint was
overall mortality, using the longest available follow-up in each study. The pairwise
RR with 95% credible interval (CrI) in Bayesian meta-analysis was the effect measure.
Results: This analysis included 2,843 patients from 13 trials. In frequentist meta-
analysis, the overall mortality did not differ in head-to-head comparison between IABP
versus MT (RR 0.86, 95% CI 0.68-1.10, p¼0.230, I2¼33.7%) or IABP versus LVAD
(RR 0.89, 95% CI 0.61-1.29, p¼0.535, I2¼0.0%). In Bayesian network meta-analysis,
overall survival beneﬁt was not signiﬁcant with IABP (RR 0.84, 95% CrI 0.56-1.24) or
LVAD (RR 0.95, 95% CrI 0.42-2.06), compared with MT. IABP or LVAD also did not
show early survival beneﬁt compared withMT, regardless of whether cardiogenic shock
was combined or not. In terms of bleeding, LVADwas theworst (versus IABP: RR 29.4,
95%CrI 5.99-221.0) (versusMT: RR41.7, 95%CrI 8.19-330.0), while IABPwasworse
thanMT (RR1.41, 95%CrI 1.01-2.08). The incidence of acute limb ischemia or vascular
complication was not different among IABP, LVAD, or MT.
Conclusions: The network meta-analysis do not support routine elective IABP or
LVAD use in high-risk PCI population. Mechanical hemodynamic support did not
show early survival beneﬁt even in the patients with cardiogenic shock, while mod-
erate to severe bleeding was signiﬁcantly more frequent with the mechanical support
use than with medical therapy. There is insufﬁcient evidence supporting routine IABP
or LVAD in patients undergoing high-risk PCI or primary PCI for the patients with
AMI accompanied by cardiogenic shock.
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Background: Transient interruption of blood ﬂow to coronaries during PCI due to
contrast dye injections, balloon inﬂations and guide-wire and stent manipulation can
lead to impairment of cardiac function. The outcomes are worse for high risk PCI and
devices that improve systemic and coronaries circulation have been applied. We aimed
to evaluate the mortality and morbidity of patients undergoing high-risk PCI that
received IABP or pLVAD (Impella and Tandem Heart).
Methods: We searched PubMed, EMBASE, and Cochrane databases from 1966
through May 2013. The studied outcomes were 30 days mortality, MACE, leg
ischemia, hemorrhagic shock, and neurologic dysfunction. We only included studies
that did not have any chance of overlapping patients from another study. We used Fixed
or Random Effect analysis using the Cochrane Handbook of Systematic Reviews.
Results: Out of 80 articles, three studies presented the studied data and were included
in the analysis. The pooled data provided a total of 572 patients, 289 receiving IABPeptal Ablation and treatments for Hypertrophic Cardiomyopathy B19
